OPKO reports Q3 net income $24.9M; sells BioReference assets for $237.5M, authorizes $100M buyback

OPKO HEALTH, INC.

2024-Q3 EPS reported -$0.10 revenue$529,504,000

Q3 revenue $173.6M vs $178.6M YoY; net income $24.9M ($0.03/diluted) vs net loss $84.5M ($0.11) in 2023.
Completed sale of select BioReference Health assets to Labcorp for $237.5M; continues oncology/urology nationwide.
Entered $250M note purchase agreement with HealthCare Royalty secured by NGENLA profit share payments from Pfizer.
Board authorized $100M share repurchase program; repurchased 14.9M shares for $23.8M in Q3 and 8.7M more through Nov 6.
Awarded $51M additional BARDA funding ($26.9M COVID, $24.1M influenza) for ModeX multispecific antibodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.